ACAD
Price
$22.85
Change
+$0.25 (+1.11%)
Updated
Dec 4, 6:59 PM EST
84 days until earnings call
RGNX
Price
$20.01
Change
+$0.34 (+1.73%)
Updated
Dec 4, 6:59 PM EST
85 days until earnings call
Ad is loading...

ACAD vs RGNX ᐉ Comparison: Which is Better to Invest?

Header iconACAD vs RGNX Comparison
Open Charts ACAD vs RGNXBanner chart's image
ACADIA Pharmaceuticals
Price$22.85
Change+$0.25 (+1.11%)
Volume$654.83K
CapitalizationN/A
REGENXBIO
Price$20.01
Change+$0.34 (+1.73%)
Volume$200.64K
CapitalizationN/A
View a ticker or compare two or three
ACAD vs RGNX Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ACAD vs. RGNX commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and RGNX is a Hold.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (ACAD: $22.85 vs. RGNX: $20.01)
Brand notoriety: ACAD and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 49% vs. RGNX: 43%
Market capitalization -- ACAD: $3.63B vs. RGNX: $844.21M
ACAD [@Biotechnology] is valued at $3.63B. RGNX’s [@Biotechnology] market capitalization is $844.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 8 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 4 bearish.
  • RGNX’s TA Score: 8 bullish, 2 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +3.30% price change this week, while RGNX (@Biotechnology) price change was +4.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.58%. For the same industry, the average monthly price growth was +26.31%, and the average quarterly price growth was +25.79%.

Reported Earning Dates

ACAD is expected to report earnings on Feb 26, 2024.

RGNX is expected to report earnings on Feb 28, 2024.

Industries' Descriptions

@Biotechnology (+5.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ACAD with price predictions.
OPEN
A.I.dvisor published
a Summary for RGNX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ACAD($3.63B) has a higher market cap than RGNX($844M). ACAD YTD gains are higher at: 43.530 vs. RGNX (-11.772). ACAD has higher annual earnings (EBITDA): -149.98M vs. RGNX (-233.66M). ACAD has more cash in the bank: 346M vs. RGNX (302M). ACAD has less debt than RGNX: ACAD (57.1M) vs RGNX (90.7M). ACAD has higher revenues than RGNX: ACAD (632M) vs RGNX (99.4M).
ACADRGNXACAD / RGNX
Capitalization3.63B844M430%
EBITDA-149.98M-233.66M64%
Gain YTD43.530-11.772-370%
P/E RatioN/A12.85-
Revenue632M99.4M636%
Total Cash346M302M115%
Total Debt57.1M90.7M63%
FUNDAMENTALS RATINGS
ACAD vs RGNX: Fundamental Ratings
ACAD
RGNX
OUTLOOK RATING
1..100
2138
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5740
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (70) in the Biotechnology industry is in the same range as RGNX (77). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as RGNX (100). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's SMR Rating (96) in the Biotechnology industry is in the same range as RGNX (97). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (40) in the Biotechnology industry is in the same range as ACAD (57). This means that RGNX’s stock grew similarly to ACAD’s over the last 12 months.

RGNX's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for ACAD (100). This means that RGNX’s stock grew significantly faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADRGNX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
Bearish Trend 13 days ago
72%
Bearish Trend 13 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 6 days ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
67%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FXR61.060.26
+0.42%
First Trust Indtls/PrdcrDurbAlphaDEX®ETF
XHYT34.01N/A
N/A
BondBloxx US HY Telecm Md Tech Sctr ETF
FTIF21.31N/A
N/A
First Trust Bloomberg Infl Snstv Eq ETF
OWNS16.79-0.08
-0.45%
CCM Affordable Housing MBS ETF
GSPY25.17-0.22
-0.86%
Gotham Enhanced 500 ETF